By Kenneth C. Frazier
Kenneth C. Frazier is Merck’s EVP and president of Global Human Health. He made his remarks during a keynote presentation...
Industry has much to fear about some elements of health reform, like drug importation and price negotiation under Medicare Part D. But the risks of inaction are even greater. Pharmaceutical companies need to ensure that they have a place at the table-and come with a detailed plan on how health reform should work.
By Kenneth C. Frazier
Kenneth C. Frazier is Merck’s EVP and president of Global Human Health. He made his remarks during a keynote presentation...
Recent studies show that spaceflight can significantly weaken astronauts’ immune systems, making them more susceptible to infections and health complications during and after missions. Understanding these changes is crucial for ensuring the safety of future long-duration space travelers.
It is unclear in a revised staff manual guide whether Commissioner's National Priority Voucher program approval “recommendations” from the drug and biologic center directors will be advisory or decisional, experts told the Pink Sheet.
Revised recommendation is based on most recent data on circulating strains in US, where KP.3 is now dominant. Novavax sticks with plans targeting the JN.1 ‘parent strain.’
Pink Sheet reporter and editors discuss the US FDA’s changes to the COVID-19 vaccine indication and its revocation of the vaccine emergency use authorizations, as well as new vaccine coverage and reimbursement questions.